INCY Incyte Corporation

115.87USD-1.64%Mkt Cap: 23.62B USDP/E: 59.12

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment o…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap23.62B USD
Enterprise Value20.19B USD
Revenue (TTM)6.01B USD
Gross Profit4.77B USD
Net Income (TTM)1.29B USD
Revenue/Share30.04 USD
Last Price115.87 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees2.8K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)59.12
P/E (Forward)13.44
PEG10.82
EV/EBITDA9.92
EV/Revenue3.36
P/S3.93
P/B4.19
EPS (TTM)1.96 USD
EPS (Forward)8.62 USD
52W Range
89.2561% of range132.58
52W High132.58 USD
52W Low89.25 USD
Profitability
Gross Margin92.76%
Oper. Margin32.22%
EBITDA Margin33.86%
Profit Margin25.03%
ROE24.90%
ROA18.49%
ROIC63.79%
ROCE24.67%
Growth
Revenue Growth14.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF1.41B USD
CapEx (TTM)83.87M USD
FCF Margin21.41%
FCF Yield5.45%
Net Debt-3.82B USD
Net Debt/EBITDA-1.88
Net Debt/FCF-2.97
Balance Sheet
Debt/Equity0.01
Current Ratio3.84
Quick Ratio3.54
Book Value/Sh27.66 USD
Cash/Share18.91 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split2:1
Split DateSep 1, 2000
Analyst Consensus
Rating2.2 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)132.17 USD
Upside (mean)+14.1%
Target Range100.00 USD – 157.00 USD
100.00+14.1% to mean157.00
# Analysts24
Ownership
Shares Out.203.83M
Float171.56M
Insiders1.88%
Institutions102.02%
Short Interest
Short Ratio5.5d
Short % Float8.87%
Short % Out.5.22%
Shares Short10.65M
Short (prev mo.)9.99M
Technical
SMA 50119.05 (-2.7%)
SMA 200109.02 (+6.3%)
Beta0.78
S&P 52W Chg12.08%
Avg Vol (30d)1.71M
Avg Vol (10d)1.50M
Technical Indicators
RSI (14)44.0
MACD0.3530
MACD Signal0.6620
MACD Hist.-0.3090
BB Upper124.01 USD
BB Middle118.90 USD
BB Lower113.79 USD
BB Width8.60%
ATR (14)3.636 USD
Vol Ratio (20d)0.66x

About Incyte (NASDAQ: INCY)

›

Incyte (NASDAQ: INCY) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 2,844 employees.

The shares were at 115.87 USD on 19 November 2026, up 9.3% over 52 weeks. Its 52-week range is 89.25 USD to 132.58 USD: the price is 12.6% below the high and 29.8% above the low.

At a market capitalisation of 23.62B USD, it trades at 59.1 times trailing earnings and 13.4 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a premium of 76% for INCY.

Incyte reports return on equity of 24.9%, an operating margin of 32.2% and revenue up 14.0% year over year.

It holds more cash than debt, a net cash position of 3.82B USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 24 analysts cover the stock, with an average rating of Buy; their mean price target of 132.17 USD is 14.1% above the current price. The next earnings report is expected on 9 February 2027.